Viral Antibodies in the Sera from Patients with Parkinson DiseaseMarttila R.J. · Arstila P. · Nikoskelainen J. · Halonen P.E. · Rinne U.K.
Departments of Neurology and Virology, University of Turku, Turku
Do you have an account?
- Rent for 48h to view
- Buy Cloud Access for unlimited viewing via different devices
- Synchronizing in the ReadCube Cloud
- Printing and saving restrictions apply
Rental: USD 8.50
Cloud: USD 20.00
Article / Publication Details
An assay of antibodies to 15 various viruses and mycoplasma pneumoniae was performed on the serum specimens from 441 patients with Parkinson disease and from 443 healthy controls matched by sex, age, and place of residence, or from a representative group of these matched pairs. The main finding was a higher herpes simplex complement-fixing antibody level in patients with Parkinson disease than in controls. Patients with Parkinson disease had higher herpes simplex antibody titers more often than did their matched controls, and the matched controls, respectively, had low titers more often than the patients. The mean herpes simplex antibody titer (log2) of the patients (4.9) was significantly higher than that of controls (4.6) (p < 0.01). This difference was also demonstrable when matched pairs were analysed for paired differences of herpes simplex antibody titers. For other viral CF and HI antibodies studied and for mycoplasma pneumoniae CF antibody, there were no significant differences either in the mean titers or in the distribution of individual titer values between the patients with Parkinson disease and the matched controls.
© 1977 S. Karger AG, Basel
Article / Publication Details
Copyright / Drug Dosage / DisclaimerCopyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.